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Abstract 
Unresectable locally advanced pancreatic cancer with 
or without metastatic disease is associated with a very 
poor prognosis. Current standard therapy is limited to 
chemotherapy or chemoradiotherapy. Few regimens 
have been shown to have a substantial survival ad-
vantage and novel treatment strategies are urgently 
needed. Thermal and laser based ablative techniques 
are widely used in many solid organ malignancies. Ini-
tial studies in the pancreas were associated with signifi-
cant morbidity and mortality, which limited widespread 
adoption. Modifications to the various applications, in 
particular combining the techniques with high quality 
imaging such as computed tomography and intraopera-
tive or endoscopic ultrasound has enabled real time 
treatment monitoring and significant improvements in 
safety. We conducted a systematic review of the litera-
ture up to October 2013. Initial studies suggest that 
ablative therapies may confer an additional survival 
benefit over best supportive care but randomised stud-
ies are required to validate these findings. 
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: Unresectable locally advanced pancreatic 
cancer with or without metastatic disease is associated 
with a very poor prognosis. Current standard therapy 
is limited to chemotherapy or chemoradiotherapy. Few 
regimens have been shown to have a substantial sur-
vival advantage and novel treatment strategies are 
urgently needed. Initial studies of ablation in the pan-
creas were associated with significant morbidity and 
mortality, which limited widespread adoption. Modifica-
tions to the various applications, in particular combining 
the techniques with high quality imaging such as com-
puted tomography and intraoperative or endoscopic 
ultrasound has enabled real time treatment monitoring 
and significant improvements in safety.
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BACKGROUND 
Pancreatic ductal adenocarcinoma (PDAC) is the tenth 
most common cancer in the UK but the fifth commonest 
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cause of  cancer death. At diagnosis more than 80% of  
patients have locally advanced or metastatic disease and 
are unsuitable for curative surgical resection. Prognosis 
in pancreatic cancer is dismal; median survival for locally 
advanced disease is just 6-10 mo, however in patients 
with metastatic disease this falls to 3-6 mo. Overall 5 year 
survival is less than 4%[1]. 
Standard options available for treating patients with 
inoperable PDAC are limited to chemotherapy, radiother-
apy, or a combination of  the two. Gemcitabine is the most 
commonly used chemotherapy agent in pancreatic cancer, 
however recent studies have shown that in combination 
with other chemotherapy agent’s further improvements in 
overall survival can be gained. A recent randomised Phase 
Ⅲ study (GemCap) reported a median survival in the 
combination gemcitabine + capecitabine group of  7.1 mo 
compared with 6.2 mo in those who received gemcitabine 
alone. The 1-year overall survival (OS) rates were 24.3% 
for combination therapy and 22% for gemcitabine alone 
(HR = 0.86, 95%CI: 0.72-1.02, P = 0.077)[2]. A further 
large European study compared gemcitabine to FOL-
FIRINOX (fluorouracil, leucovorin, irinotecan and oxali-
platin) and demonstrated a significant survival advantage 
in the FOLFIRINOX group compared with gemcitabine 
alone (median 11.1 mo vs 6.8 mo)[3]. The phase Ⅲ MPACT 
study found that weekly intravenous nab-paclitaxel with 
gemcitabine resulted in a significantly higher overall sur-
vival compared to gemcitabine monotherapy (8.5 mo vs 6.7 
mo, HR = 0.72, P < 0.0001)[4]. 
Given that so few patients with PDAC are suitable for 
curative surgery and most have only a limited response to 
chemotherapy; tumour debulking or interstitial ablation 
has been investigated as a potential additional therapy. 
A recent systematic review compared R2 resections to 
palliative bypass alone in the management of  advanced 
PDAC. A small non-significant survival advantage was 
observed in the R2 resection group; 8.2 mo compared 
to 6.7 mo in the palliative bypass group. However pa-
tients undergoing R2 resections had a significantly higher 
morbidity (RR = 1.75, 95%CI: 1.35-2.26, P < 0.0001), 
mortality (RR = 2.98, 95%CI: 1.31-6.75, P = 0.009) and 
longer hospital stay (mean difference, 5 d, 95%CI: 1-9 d, 
P = 0.02), hence R2 resections are not recommended as 
part of  the standard management of  PDAC[5]. However 
minimally invasive ablative therapies delivered percutane-
ously or endoscopically have become part of  standard 
therapy in many other solid organ tumours, particularly 
in patients with inoperable disease or who are unfit for 
surgical resection[6]. Early studies of  local ablation in the 
pancreas were associated with high morbidity and mortal-
ity[7]. However improvements in delivery and in particular 
combining the technology with high quality real-time im-
aging, has reduced associated complications. The safety 
and efficacy of  each ablative therapy in non-operable 
PDAC will be evaluated in this review. 
RESEARCH METHODOLOGY
The primary aim of  this review was to assess safety and 
efficacy of  each ablation therapy in the treatment of  lo-
cally advanced or metastatic PDAC. Secondary endpoints 
included improvements in overall survival, changes in 
symptoms, tumour markers or performance status where 
available. A systematic literature search was performed 
using the PubMed, EMBASE databases and the Co-
chrane Library for studies published in the English lan-
guage up to 1st October 2013. MeSH terms were decided 
by a consensus of  the authors and were (radiofrequency 
ablation, catheter ablation, photodynamic therapy, PDT, 
cryoablation, cryosurgery, laser, high intensity focused 
ultrasound ablation, microwave, electroporation) and 
(pancreas OR pancreatic), and were restricted to the title, 
abstract and keywords. Only articles, which described 
ablation in unresectable PDAC, were included. Articles 
that described the use of  ablative therapies in premalig-
nant pancreatic disease were excluded but outcomes are 
summarised in Table 1. Similarly studies that included 
non-ablative therapies were also excluded but have been 
summarised in Table 2. Any study with fewer than four 
patients and those reporting on tumours that did not 
originate in the pancreas were excluded. In cryoablation 
and high frequency focused ultrasound of  the pancreas, 
many of  the largest case-series are published in non-
English language medical journals. Although articles not 
published in the English language were excluded from 
this systematic review, if  an English language abstract 
was available the results were included in the summary 
tables. All references were screened for potentially rel-
evant studies not identified in the initial literature search. 
The following variables were extracted for each report 
when available: number of  patients, disease extent, device 
used and settings, distance of  probe from surrounding 
structures, duration of  therapy and number of  ablations 
applied, additional safety methods used. Thirty-two pa-
pers were included (Figure 1). 
THERMAL ABLATIVE TECHNIQUES
Radiofrequency ablation
Radiofrequency ablation (RFA) causes tissue destruction 
through the application of  a high frequency alternating 
current that generates high local temperatures leading 
to a coagulative necrosis. The technique has been widely 
used in many solid organ malignancies and is now part 
of  standard therapy in several tumours including hepa-
tocellular carcinoma[6]. The first application of  RFA in 
the normal porcine pancreas was described in 1999. Al-
though this application was performed under EUS guid-
ance[8] it has nearly always been delivered intraoperatively 
(rarely percutaneously) in combination with palliative by-
pass surgery[9]. Although RFA was deemed to be feasible 
and safe in animal studies[8], early clinical applications 
in the pancreas were associated with unacceptably high 
rates of  morbidity (0%-40%) and mortality (0%-25%) 
(Table 3)[7,10-14]. Most RFA of  pancreatic tumours has 
been performed using the Cool-tip™ RF Ablation sys-
tem (Radionics). Many of  the complications arose as a 
result of  inadvertent damage to structures adjacent to 
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the zone of  ablation such as the normal pancreas, duo-
denum, biliary tree or peri-pancreatic vasculature. These 
early studies applied high temperatures (> 90 ℃) and 
multiple rounds of  ablation to treat large tumours in the 
head of  the pancreas in one session[13]. An ex-vivo study 
of  the thermal kinetic characteristics of  RFA found that 
the optimal settings for RFA in the pancreas to prevent 
injury to the adjacent viscera was 90 ℃ applied for 5 
min[15]. Subsequent clinical studies that reduced the RFA 
temperature from 105 ℃ to 90 ℃, reported only minimal 
RFA-related complications[7]. Active cooling of  the major 
vessels and duodenum with saline during intraoperative 
RFA and observing at least a 0.5 cm area between the 
zone of  ablation and major structures, reduced compli-
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  Author Premalignant lesion n Treatment Median area of 
ablation, mm 
(range)
Outcome Complications
  Gan et al[46] Cystic tumours of the 
pancreas
25 EUS guided ethanol 
lavage
19.4 (6-30) Complete 
resolution 35%
None
  Oh et al[73] Cystic tumours of the 
pancreas
14 EUS guided ethanol 
lavage + paclitaxel
  25.5 (17-52) Complete 
resolution in 79%
Acute pancreatitis (n = 1)
Hyperamylasaemia (n = 6) Abdominal 
pain (n = 1)
  Oh et al[74] Cystic tumours of the 
pancreas
10 EUS guided ethanol 
lavage + paclitaxel
  29.5 (20-68) Complete 
resolution in 60%
Mild pancreatitis (n = 1)
  DeWitt et al[75] Cystic tumours of the 
pancreas
42 Randomised double blind 
study: Saline vs ethanol
  22.4 (10-58) Complete 
resolution in 33%
Abdominal pain at 7 d (n = 5)
Pancreatitis (n = 1)
Acystic bleeding (n = 1)
  Oh et al[47] Cystic tumours of the 
pancreas
52 EUS guided ethanol 
lavage + paclitaxel
  31.8 (17-68) Complete 
resolution in 62%
Fever (1/52)
Mild abdominal discomfort (1/52)
Mild pancreatitis (1/52)
Splenic vein obliteration (1/52)
  Levy et al[76] PNET   8 EUS guided ethanol 
lavage (5 patients) and 
intra-operative ultrasound 
guided (IOUS) ethanol 
lavage (3 patients)
16.6 (8-21) Hypoglycemia 
symptoms 
disappeared 5/8 
and significantly 
improved 3/8
EUS guided: No complications. 
IOUS-guided ethanol injection: 
Minor peritumoral bleeding (1/3), 
pseudocyst (1/3), pancreatitis (1/3)
  Pai et al[21] Cystic tumours 
of the pancreas + 
neuroendocrine 
tumours
  8 EUS guided RFA Mean size pre 
RFA, 38.8 mm vs 
mean size post 
RFA, 20 mm
Complete ablation 
in 25% (2/8)
2/8 patients had mild abdominal pain 
that resolved in 3 d
Table 1  Use of ablative therapies to treat cystic and solid premalignant lesions of the pancreas 
RFA: Radiofrequency ablation; EUS: Endoscopic ultrasound; PNET: Pancreatic neuroendocrine tumour.
  Author Therapy Patients n Outcome and survival Complications
  Chang et al[77] Cytoimplant (mixed lymphocyte 
culture)
Unresectable 
PDAC
  8 Median survival: 13.2 mo. 2 partial 
responders and 1 minor response
7/8 developed low-grade fever
3/8 required biliary stent placement
  Hecht et al[78] ONYX-015 (55-kDa gene-deleted 
adenovirus) + Ⅳ gemcitabine
Unresectable 
PDAC
21 No patient showed tumour 
regression at day 35. After 
commencement of gemcitabine, 
2/15 had a partial response
Sepsis: 2/15
Duodenal perforation: 2/15
  Hecht et al[79]
  Chang et al[80,81]
TNFerade (replication-deficient 
adenovector containing human 
tumour necrosis factor (TNF)-α 
gene) 
Locally 
advanced 
PDAC
50 Response: One complete response, 
3 partial responses. Seven patients 
eventually went to surgery, 6 had 
clear margins and 3 survived > 24 
mo
Dose-limiting toxicities of pancreatitis 
and cholangitis were observed in 
3/50
  Herman et al[82] Phase Ⅲ study of standard 
care plus TNFerade (SOC + 
TNFerade) vs standard care 
alone (SOC) 
Locally 
advanced 
PDAC
304 (187 SOC 
+ TNFerade)
Median survival: 10.0 mo for 
patients in both the SOC + 
TNFerade and SOC arms [hazard 
ratio (HR), 0.90, 95%CI: 0.66-1.22, P 
= 0.26]
No major complications. Patients in 
the SOC + TNFerade arm experienced 
more grade 1 to 2 fever than those in 
the SOC alone arm (P < 0.001) 
  Sun et al[83] EUS-guided implantation of 
radioactive seeds (iodine-125)
Unresectable 
PDAC
15 Tumour response: "partial" in 27% 
and "minimal" in 20%. Pain relief: 
30%
Local complications (pancreatitis and 
pseudocyst formation) 3/15. Grade 
Ⅲ hematologic toxicity in 3/15
  Jin et al[84] EUS-guided implantation of 
radioactive seeds (iodine-125)
Unresectable 
PDAC 
22 Tumour response: “partial” in 3/22 
(13.6%)
No complications
Table 2  Endoscopic ultrasound administered non-ablative anti-tumour therapies for pancreatic ductal adenocarcinoma
PDAC: Pancreatic ductal adenocarcinoma; EUS: Endoscopic ultrasound.
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quiring transfusion[19]. In a further study, 7 patients with 
unresectable PDAC received EUS guided RFA using 
the monopolar radiofrequency (RF) catheter (1.2 mm 
Habib EUS-RFA catheter, Emcision Ltd, London). The 
tumour was shown to decrease in size in all cases and 
only one patient developed mild pancreatitis[20]. Long-
term follow up is not available on the efficacy of  these 
new catheters. Early clinical studies have also used the 
Habib EUS RFA catheter to treat cystic tumours of  the 
pancreas (Table 1)[21]. 
Microwave ablation
Microwave (MW) current is produced by a generator 
connected via a coaxial cable to 14-gauge straight MW 
antennas with a 3.7 cm or 2 cm radiating section. One 
or two antennae are then inserted into the tumour for 10 
min. The largest case series of  microwave ablation in lo-
cally advanced PDAC includes 15 patients. Although MW 
ablation can be performed percutaneously or intraopera-
tively[22], in this series it was performed intraoperatively 
at the time of  palliative bypass surgery. All tumours were 
located in the head or body of  the pancreas and had an 
average size of  6 cm (range 4-8 cm); none had distant 
metastasis on imaging. Partial necrosis was achieved in 
all patients and there was no major procedure-related 
morbidity or mortality. However minor complications 
were seen in 40% (mild pancreatitis, asymptomatic hy-
peramylasia, pancreatic ascites, and minor bleeding). The 
longest survival of  an individual patient in this series was 
22 mo[23]. 
Cryoablation
The successful use of  cryoablation in the pancreas was 
first reported in primate experiments in the 1970s[24]. 
However its potential application as a therapy in pancre-
atic cancer was not described for a further 20 years[25]. 
Cryoablation is most commonly performed intra-
operatively under ultrasound guidance. Small lesions (< 3 
cm) can be reliably frozen with a single, centrally placed 
probe but larger tumours require the placement of  mul-
tiple probes or sequential treatments. Most studies have 
used the argon-gas-based cryosurgical unit (Endocare, 
Inc., CA, United States) and employ a double “freeze/
thaw” cycle. The tumour is cooled to -160 ℃ and the 
resulting iceball monitored with ultrasound to ensure the 
frozen region encompasses the entire mass and does not 
compromise local structures. The tissue is then allowed 
to slowly thaw to 0 ℃ and a second cycle of  freezing is 
performed after any necessary repositioning of  the cryo-
probes. Like in many of  the RFA studies, the authors ad-
vocated a 0.5 cm margin of  safety from major structures 
and that ideally the procedure should be performed at the 
same time as palliative bypass surgery or endoscopic bili-
ary and duodenal stenting. Ablation of  liver metastases 
can also be performed simultaneously[26]. 
The largest experience of  intraoperative and per-
cutaneous cryoablation in pancreatic cancer has been 
reported from Asia. To date more than 200 patients with 
cations[10,16,17]. Since most of  the mortality resulted from 
uncontrollable gastrointestinal haemorrhage from ablated 
tumours in the head of  the pancreas, some authors have 
recommended this probe should only be employed in 
body or tail tumours[10,16]. 
All studies have demonstrated that RFA leads to tu-
mour necrosis and a decrease of  tumour volume[9,12,17,18]. 
Some studies have also observed an improvement in 
tumour related symptoms, in particular a reduction of  
back pain and analgesia requirements. Tumour mark-
ers (carbohydrate antigen 19-9) also decrease following 
effective ablation[16]. Although all patients treated with 
RFA ultimately developed disease progression[9,11,12,17,18], 
when compared to patients with advanced disease who 
received standard therapy in a non-randomised cohort 
study, patients who received combination therapy had 
prolonged survival (33 mo vs 13 mo, P = 0.0048)[11]. 
However, this was a single centre study that only in-
cluded 25 patients (12 receiving RFA). An earlier non-
randomised study did not demonstrate the same survival 
advantage[12]. Spiliotis et al[11] also evaluated overall sur-
vival following RFA according to tumour stage. Patients 
with stage Ⅲ disease had a significant improvement in 
survival following RFA compared to patients with the 
same stage of  disease receiving best supportive care (P = 
0.0032). In contrast, no difference in overall survival was 
shown in patients with metastatic PDAC, following RFA 
treatment (P = 0.1095). Larger studies, in combination 
with systemic chemotherapy, would be needed to evalu-
ate any potential role of  RFA in patients with metastatic 
disease.
Recently two new RFA probes have been developed 
that can be placed down the working channel of  an en-
doscope, enabling RFA to be administered under EUS 
guidance. Twenty-two patients with locally advanced 
PDAC were treated with the cryotherm probe (CTP) 
(ERBE Elektromedizin GmbH, Tübingen, Germany) 
that incorporates radiofrequency ablation with cryogenic 
cooling. The probe was sited successfully in 16 patients 
(72.8%); stiffness of  the gastrointestinal wall and tumour 
prevented placement in the others. Following the pro-
cedure three patients reported mild abdominal pain and 
one experienced minor gastrointestinal bleeding, not re-
PubMed, EMBASE, cochrane library
n  = 10978
Duplicate articles, review articles and 
non-English publications which were 
excluded n  = 10946
Studies included in the analysis
n  = 32
Figure 1  Systematic review schema.
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unresectable pancreatic cancer have undergone cryoabla-
tion alone or in combination with other therapies (Table 
4). Effective control of  pain, normalisation of  CA 19-9, 
improvement in performance status and prolonged sur-
vival have all been reported following cryoablation. Rates 
of  significant complications appear to be lower than in 
other methods of  ablation. Although some patients did 
encounter delayed gastric emptying following the treat-
ment, this commonly settled with conservative manage-
ment within a few days. Studies to date are summarised 
in Table 5. The process has also been shown to initiate 
antiangiogenesis and a systemic immunological response, 
which may promote additional anti-tumour effects[27,28]. 
However evaluation through larger studies will be neces-
sary to fully determine this effect. 
Early clinical studies have also combined the admin-
istration of  cryotherapy with immunotherapy. In a study 
of  106 patients with unresectable PDAC, 31 received cry-
oimmunotherapy, 36 cryotherapy, 17 immunotherapy and 
22 chemotherapy. Median overall survival was higher in 
the cryoimmunotherapy (13 mo) and cryotherapy groups 
(7 mo) than in the chemotherapy group (3.5 mo; both 
P < 0.001) and was higher in the cryoimmunotherapy 
group than in the cryotherapy (P < 0.05) and immuno-
therapy groups (5 mo; P < 0.001)[29]. 
LASER BASED ABLATIVE THERAPY
Photodynamic therapy
Photodynamic therapy (PDT) results in tumour ablation 
by exposure to light following an intravenous injection of  
a photosensitiser [e.g., meso-tetra(hydroxyphenyl)chlorin 
(mTHPC), porfimer sodium or verteporfin] which is 
taken up by cells. It leads to a predictable zone of  abla-
tion within the tumour. To date, light has been delivered 
via small optic fibers which have nearly always been 
positioned percutaneously under image guidance (e.g., 
CT)[30-32]. However these fibers can pass through a 19G 
needle, so administration under endoscopic ultrasound 
guidance is feasible. 
The first Phase Ⅰ trial of  PDT in locally advanced 
PDAC was conducted in 2002. Substantial tumour necro-
  Study n   Patients Study Outcome Complications
  Patiutko et al[25] 
  (non-English article)
30 Locally advanced 
PDAC
Combination of cryosurgery 
and radiation
Pain relief and improvement 
in performance status: 30/30
Not reported
  Kovach et al[52]   9 Unresectable PDAC Phase Ⅰ study of 
intraoperative cryoablation 
under US guidance. 
Four had concurrent 
gastrojejunostomy
7/9 discharged with non-
intravenous analgesia and 
1/9 discharged with no 
analgesia
No complications reported
  Li et al[53] 
  (non-English article)
44 Unresectable PDAC Intraoperative cryoablation 
under US guidance
Median overall survival: 14 
mo
40.9% (18/44) had delayed gastric 
empting. 6.8% (3/44) had a bile and 
pancreatic leak
  Wu et al[54]
  (non-English article)
15 Unresectable PDAC Intraoperative cryoablation 
under US guidance
Median overall survival: 
13.4 mo
1/15 patients developed a bile leak 
  Yi et al[55] 
  (non-English article)
  8 Unresectable PDAC Intraoperative cryoablation 
under US guidance
Not reported 25% (2/8) developed delayed gastric 
emptying
  Xu et al[26] 38 Locally advanced 
PDAC, 8 had liver 
metastases
Intraoperative or 
percutaneous cryoablation 
under US or CT guidance 
+ (125) iodine seed 
implantation
Median overall survival: 12 
mo. 19/38 (50.0%) survived 
more than 12 mo
Acute pancreatitis: 5/38 (one has 
severe pancreatitis)
  Xu et al[56] 49 Locally advanced 
PDAC, 12 had liver 
metastases
Intraoperative or 
percutaneous cryoablation 
under US or CT guidance 
and (125) iodine seed 
implantation. Some patients 
also received regional celiac 
artery chemotherapy
Median survival: 16.2 mo. 
26 patients (53.1%) survived 
more than 12 mo
Acute pancreatitis: 6/49 (one had 
severe pancreatitis)
  Li et al[57] 68 Unresectable PDAC 
requiring palliative 
bypass
Retrospective case-series of 
intraoperative cryoablation 
under US guidance, followed 
by palliative bypass
Median overall survival: 
30.4 mo (range 6-49 mo)
Postoperative morbidity: 42.9%. 
Delayed gastric emptying occurred 
in 35.7%
  Xu et al[58] 59 Unresectable PDAC Intraoperative or 
percutaneous cryotherapy
Median survival: 8.4 mo.
Overall survival at 12 mo: 
34.5%
Mild abdominal pain: 45/59 (76.3%)
Major complications (bleeding, 
pancreatic leak): 3/59 (5%)
1/59 developed a tract metastasis
  Niu et al[29] 36 (CT)
31 (CIT)
Metastatic PDAC Intraoperative cryotherapy 
(CT) or cryoimmunotherapy 
(CIT) under US guidance
Median overall survival in 
CIT: 13 mo 
CT: 7 mo
Not reported
Table 4  Studies of cryoablation in pancreatic ductal adenocarcinoma
PDAC: Pancreatic ductal adenocarcinoma.
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sis was achieved in all 16 patients included in the study. 
Median survival after PDT was 9.5 mo (range 4-30 mo). 
44% (7/16) were alive one year after PDT. Two of  the 
patients who had a pancreatic tumor which involved the 
gastroduodenal artery developed significant gastrointesti-
nal bleeding following the procedure. However both were 
managed endoscopically with transfusion, without the 
need for surgery[30]. 
A significant drawback of  the early PDT treatments 
was that patients had to spend several days in subdued 
lighting following the treatment to prevent complications 
from skin necrosis. However, newer photosensitisers with 
a shorter drug-light interval and faster drug elimination 
time have been developed (e.g., verteporfrin) and have 
been shown in preclinical and early clinical studies to 
have a similar efficacy and safety profile to mTHPC[33]. 
A Phase Ⅰ study by our group evaluated verteporfin-
mediated PDT in 15 patients with unresectable locally 
advanced pancreatic cancer (Vertpac-01) (Table 5)[31,32]. 
The study was designed in 2 parts: the first 13 patients 
were treated with a single-fibre, with the following 2 
patients being treated with light from multiple fibers. A 
predictable zone of  necrosis surrounding the fibers was 
achieved. No instances of  photosensitivity were reported 
and only one patient developed cholangitis. Patient went 
on to receive palliative gemcitabine chemotherapy 28 d 
after ablation. 
YAG Laser
The neodymium-doped yttrium aluminium garnet (Nd:
YAG) laser has been used to ablate pancreatic tumours in 
animal models[34]. A well demarcated area of  necrosis and 
no complications were achieved, suggesting the potential 
for this therapy, but to date there have been no clinical 
studies.
NON-THERMAL, NON-LASER METHODS 
OF ABLATION
Many of  the studies of  thermal and light ablation tech-
niques in locally advanced and metastatic PDAC have sug-
gested that cytoreduction may improve survival. However 
in the initial clinical studies some of  the techniques were 
associated with unacceptably high rates of  complications. 
This has led to a search for non-thermal alternative abla-
tive therapies for use in PDAC.
High-intensity focused ultrasound
High intensity focused ultrasound (HIFU) therapy is a 
non-invasive method of  ablation. Ultrasound energy 
from an extracorporeal source is focused on the pan-
creatic tumour to induce thermal denaturation of  tissue 
without affecting surrounding organs[35]. Multiple non-
randomised studies and case series, largely from Asia, 
have reported preliminary clinical experiences of  using 
HIFU in PDAC. They have demonstrated that the tech-
nique is able to achieve tumour necrosis with relatively 
few side effects (Table 6). Recently a HIFU transducer 
has been designed which can be attached to an EUS 
scope to deliver HIFU locally to pancreatic tumours, thus 
preventing occasional burns to the skin. Initial animal 
studies have demonstrated that it can successfully abate 
the normal pancreas and liver[36]. 
Irreversible electroporation 
NanoKnife® (Angiodynamics, Inc., NY, United States) 
or irreversible electroporation (IRE) is an emerging non-
thermal ablative technique which uses electrodes, placed 
in the tumour, to deliver up to 3 kV of  direct current. 
This induces the formation of  nanoscale pores within 
the cell membrane of  the targeted tissue, which irrevers-
ibly damages the cell’s homeostatic mechanism, causing 
apoptosis. The United States Food and Drug Administra-
tion have recently approved the technique for use in the 
pancreas. 
One of  the major advantages of  this technique is 
that it can be used in tumours that are in close proxim-
ity to peri-pancreatic vessels without risk of  vascular 
trauma. The largest series of  percutaneous IRE in PDAC 
includes 14 patients who had unresectable tumours and 
were not candidates for, or were intolerant of  standard 
therapy[37]. The procedure was performed under general 
anaesthesia with complete muscle paralysis. Two patients 
  Study n   Study Photosensitiser Number of 
fibres
Number of 
ablations
Outcome and survival Complications
  Bown et al[30] 16 CT guided percutaneous 
PDT to locally advanced 
but inoperable PDAC 
without metastatic 
disease
mTH-PC Single 1 Tumour necrosis: 
16/16. 
Median survival: 
9.5 mo. 44% (7/16) 
survived > 1 year
Significant gastrointestinal 
bleeding: 2/16 (controlled 
without surgery)
  Huggett et al[31,32] 13 + 2 CT guided percutaneous 
PDT to locally advanced 
but inoperable PDAC 
without metastatic 
disease
Verteporfrin Single (13)
Multiple (2)
1 Technically feasible: 
15/15. Dose dependent 
necrosis occurred
Single fibre: No 
complications.
Multiple fibres: CT evidence 
of inflammatory change 
anterior to the pancreas, no 
clinical sequelae
Table 5  Studies of photodynamic therapy in pancreatic ductal adenocarcinoma
PDAC: Pancreatic ductal adenocarcinoma; CT: Computed tomography.
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subsequently underwent surgery after IRE and both had 
margin-negative resections; both remain disease-free after 
11 and 14 mo, respectively. Complications included spon-
taneous pneumothorax during anaesthesia (n = 1) and 
pancreatitis (n = 1); both patients recovered completely. 
No deaths were related to the procedure but the three 
patients with metastatic disease subsequently died from 
disease progression.
COMBINING ABLATIVE THERAPIES WITH 
BILIARY STENTING
Tumours of  the head of  the pancreas commonly cause 
distal biliary obstruction, which is managed in most cases 
by an endoscopically inserted self-expanding metal stent 
(SEMS). However due to tumour ingrowth SEMS are 
associated with a shorter patency time than bypass sur-
gery. Hence there has been a growth in interest in using 
ablative therapies such as PDT or RFA to prolong stent 
patency or to unblock a SEMS, which is already in situ. 
Randomised studies comparing PDT with biliary stent-
ing to stenting alone have had conflicting results. Initial 
studies reported prolonged stent patency and improved 
survival after PDT[38,39]. However, a recent UK phase Ⅲ 
study closed early as overall survival was longer in those 
treated with stenting alone[40]. The use of  RFA in combi-
nation with SEMS placement has been reported in two 
small studies to date (Table 3). The investigators showed 
that the median bile duct diameter increased following 
endobiliary RFA and that 86% (19/22) of  the SEMS 
were patent at 90 d[41,42]. Emerging evidence also suggests 
that endobiliary RFA may confer some early survival 
benefit in patients with malignant biliary obstruction 
independent of  stent blockage and chemotherapy[41]. Oc-
casionally centres have used RFA alone to achieve biliary 
drainage but results of  on-going randomised controlled 
trials are awaited for validation of  this technique[43]. Cur-
rent guidance from the National Institute for Health and 
Care Excellence in the United Kingdom recommends 
  Study n Study Outcome and survival Complications
  Wang et al[59]
  (non-English article)
  15 HIFU monotherapy in late stage PDAC Pain relief: 13/13 (100%) Mild abdominal pain (2/15)
  Xie et al[60]
  (non-English article)
  41 HIFU alone vs HIFU + gemcitabine in 
locally advanced PDAC
Pain relief: HIFU (66.7%), None
HIFU + gemcitabine (76.6%)
  Xu et al[61]
  (non-English article)
  37 HIFU monotherapy in advanced PDAC Pain relief: 24/30 (80%) None
  Yuan et al[62]
  (non-English article)
  40 HIFU monotherapy Pain relief: 32/40 (80%) None
  Wu et al[63]     8 HIFU in advanced PDAC Median survival: 11.25 mo None
Pain relief: 8/8
  Xiong et al[64]   89 HIFU in unresectable PDAC Median survival: 26.0 mo (stage Ⅱ), 
11.2 mo (stage Ⅲ) and 5.4 mo (stage Ⅳ)
Superficial skin burns (3.4%), 
subcutaneous fat sclerosis (6.7%), 
asymptomatic pseudocyst (1.1%)
  Zhao et al[65]   37 Phase Ⅱ study of gemcitabine + HIFU 
in locally advanced PDAC
Overall survival: 12.6 mo (95%CI: 
10.2-15.0 mo)
Pain relief: 78.6%
16.2% experienced grade 3 or 4 
neutropenia, 5.4% developed grade 
3 thrombocytopenia, 8% had nausea 
vomiting
  Orsi et al[66]     6 HIFU in unresectable PDAC Pain relief: 6/6 (100%) Portal vein thrombosis (1/6)
  Sung et al[67]   46 Stage III or Ⅳ PDAC Median survival: 12.4 mo. Overall 
survival at 12 mo was 30.4%
Minor complications (abdominal pain, 
fever and nausea): 57.1% (28/29)
Major complications 
(pancreaticoduodenal fistula, gastric 
ulcer or skin burns): 10.2% (5/49)
  Wang et al[68]   40 Advanced PDAC Median overall survival: 10 mo (stage 
Ⅲ) and 6 mo (stage Ⅳ). 
Pain relief: 35/40 (87.5%)
None
  Lee et al[69]   12 HIFU monotherapy in unresectable 
PDAC (3/12 received chemotherapy)
Median overall survival for those 
receiving HIFU alone (9/12 patients): 
10.3 mo
Pancreatitis: 1/12
  Li et al[70]   25 Unresectable PDAC Median overall survival: 10 mo. 42% 
survived more than 1 year. Perfor-
mance status and pain levels improved: 
23/25
1st degree skin burn: 12%
Mortality: 0%
  Wang et al[71] 224 Advanced PDAC Not reported Abdominal distension, anorexia and 
nausea: 10/ 224 (4.5%). Asymptomatic 
vertebral injury: 2/224
  Gao et al[72]   39 Locally advanced PDAC Pain relief: 79.5% 
Median overall survival: 11 mo. 30.8% 
survived more than one year
None
Table 6  Studies of high intensity focused ultrasound in pancreatic ductal adenocarcinoma
HIFU: High intensity focused ultrasound; PDAC: Pancreatic ductal adenocarcinoma. 
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that this treatment should only be carried out in specialist 
centres in the context of  clinical trials[44]. 
ENDOSCOPIC ULTRASOUND GUIDED 
NON-ABLATIVE LOCAL THERAPIES
Systemic chemotherapy agents are often associated with 
significant side effects, which can result in patients having 
to stop therapy or undergo dose reduction. Several groups 
have therefore explored using local anti-tumour agents in 
PDAC. The outcomes are summarised in Table 2.
PREMALIGNANT LESIONS OF THE 
PANCREAS 
Some investigators have used similar ablative methods 
in PDAC to ablate premalignant solid and cystic lesions 
of  the pancreas. Cystic lesions of  the pancreas are an 
increasingly common clinical finding and some possess 
premalignant potential; longterm surveillance or surgery 
or pancreatic surgery is therefore recommended in accor-
dance with international guidance[45]. Given the morbidity 
of  surgery and uncertainties of  surveillance for essential-
ly benign disease, minimally invasive ablative therapies are 
increasingly becoming an attractive alternative treatment. 
An EUS-guided injection of  alcohol has been re-
ported to have reasonable efficacy for achieving complete 
ablation of  pancreatic cystic tumours (35%-62%). How-
ever, total cyst ablation was rare in septated cysts and the 
technique was associated with complications (pain and 
pancreatitis) in between 4%-20% of  cases[46,47]. Occasion-
al case reports have described using EUS guided alcohol 
injection to successfully ablate hepatic metastases[48] and 
pancreatic gastrointestinal stromal tumours[49]. Small case 
series have demonstrated EUS guided RFA can also be 
used safely for this indication[21]. Further validation will 
come from larger Phase Ⅱ studies.
CONCLUSION
Ablative therapies for unresectable pancreatic cancer are 
an attractive emerging therapy. All studies demonstrated 
that ablation is feasible and reproducible. Many of  the 
early concerns that surrounded safety have been ad-
dressed with device development and modification of  
technique. Long-term survival data for many of  the tech-
niques is absent currently. Ultimately large prospective 
randomised studies will be required to assess the efficacy 
of  these techniques and define their position in future 
treatment algorithms for the management of  locally ad-
vanced pancreatic cancer. 
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